- Home
- WNW vs NBTX Comparison
WNW vs NBTX Comparison
Compare WNW & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- NBTX
- Stock Information
- Founded
- WNW 2015
- NBTX 2003
- Country
- WNW China
- NBTX France
- Employees
- WNW N/A
- NBTX N/A
- Industry
- WNW Catalog/Specialty Distribution
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- NBTX Health Care
- Exchange
- WNW Nasdaq
- NBTX Nasdaq
- Market Cap
- WNW 200.5M
- NBTX 201.9M
- IPO Year
- WNW 2020
- NBTX 2020
- Fundamental
- Price
- WNW $0.19
- NBTX $3.75
- Analyst Decision
- WNW
- NBTX Strong Buy
- Analyst Count
- WNW 0
- NBTX 1
- Target Price
- WNW N/A
- NBTX $12.00
- AVG Volume (30 Days)
- WNW 3.4M
- NBTX 8.9K
- Earning Date
- WNW 11-15-2024
- NBTX 09-18-2024
- Dividend Yield
- WNW N/A
- NBTX N/A
- EPS Growth
- WNW N/A
- NBTX N/A
- EPS
- WNW N/A
- NBTX N/A
- Revenue
- WNW $380,345.00
- NBTX $45,220,186.00
- Revenue This Year
- WNW N/A
- NBTX N/A
- Revenue Next Year
- WNW N/A
- NBTX N/A
- P/E Ratio
- WNW N/A
- NBTX N/A
- Revenue Growth
- WNW N/A
- NBTX 526.17
- 52 Week Low
- WNW $0.16
- NBTX $2.76
- 52 Week High
- WNW $3.50
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- WNW 32.91
- NBTX 53.25
- Support Level
- WNW $0.18
- NBTX $3.60
- Resistance Level
- WNW $0.21
- NBTX $3.95
- Average True Range (ATR)
- WNW 0.02
- NBTX 0.19
- MACD
- WNW 0.06
- NBTX -0.01
- Stochastic Oscillator
- WNW 38.46
- NBTX 38.18
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.